AN2 Therapeutics, Inc.
ANTX
$1.24
-$0.06-4.62%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
10/28/2025
-
Simply Wall St
9/4/2025
-
Simply Wall St
8/12/2025
-
GuruFocus
8/12/2025
-
GuruFocus
8/12/2025
-
The Fly
8/12/2025
-
Business Wire
8/12/2025
-
GuruFocus
8/12/2025
-
GuruFocus
8/12/2025
-
The Fly
8/12/2025
-
Business Wire
7/23/2025
-
GuruFocus
7/23/2025
-
GuruFocus
7/23/2025
-
GuruFocus
7/23/2025
-
The Fly
7/23/2025
-
Business Wire
6/30/2025
-
GuruFocus
6/30/2025
-
GuruFocus
6/30/2025
-
TipRanks Financial Blog
6/30/2025
-
The Fly
6/30/2025
-
Business Wire
5/30/2025
-
GuruFocus
5/29/2025
-
GuruFocus
5/29/2025
-
GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 331 9090
Address
1800 El Camino Real
Menlo Park, CA 94027
Menlo Park, CA 94027
Country
Year Founded
Business Description
Sector
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase...
more